Why need viral vector characterization? Cell and gene therapies for various rare diseases are currently undergoing clinical trials worldwide. The rapid development in this field has led to an increase ...

In 2023, industry is witnessing a renaissance in viral vector characterization. Spurred by widespread biopharma investment to engineer a new wave of novel capsids and faced with newly launched QbD ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adenoassociated virus (AAV) serotypes 2 and 8, enabling determination of capsid ...

This is a preview. Log in through your library . Abstract We prove that a holomorphic vector bundle E over a compact connected Kahler manifold admits a flat connection, with a finite group as its ...

The use of adeno-associated viruses (AAV) as gene delivery vectors has vast potential for the treatment of many severe human diseases. A small group of intensively studied AAV capsids have been ...

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...